KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Long-Term Investments (2016 - 2025)

Abbott Laboratories' Long-Term Investments history spans 17 years, with the latest figure at $918.0 million for Q4 2025.

  • For Q4 2025, Long-Term Investments rose 3.61% year-over-year to $918.0 million; the TTM value through Dec 2025 reached $918.0 million, up 3.61%, while the annual FY2025 figure was $918.0 million, 3.61% up from the prior year.
  • Long-Term Investments for Q4 2025 was $918.0 million at Abbott Laboratories, down from $951.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $958.0 million in Q2 2025 and bottomed at $734.0 million in Q2 2022.
  • The 5-year median for Long-Term Investments is $814.0 million (2021), against an average of $834.0 million.
  • The largest annual shift saw Long-Term Investments dropped 8.82% in 2022 before it increased 15.74% in 2024.
  • A 5-year view of Long-Term Investments shows it stood at $816.0 million in 2021, then decreased by 6.13% to $766.0 million in 2022, then rose by 4.31% to $799.0 million in 2023, then increased by 10.89% to $886.0 million in 2024, then rose by 3.61% to $918.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABT's Long-Term Investments are $918.0 million (Q4 2025), $951.0 million (Q3 2025), and $958.0 million (Q2 2025).